Advertisement

Topics

Zogenix Reports Positive Top-line Results From Phase 3 Clinical Trial Of ZX008

09:56 EDT 13 Jul 2018 | Pharmaceutical Processing

Zogenix reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of children and young adults with Dravet syndrome.
Contributed Author: 
Zogenix, Inc.

Original Article: Zogenix Reports Positive Top-line Results From Phase 3 Clinical Trial Of ZX008

NEXT ARTICLE

More From BioPortfolio on "Zogenix Reports Positive Top-line Results From Phase 3 Clinical Trial Of ZX008"

Advertisement
Quick Search
Advertisement
Advertisement